Blood Product Market Overview
The global Blood Product market was valued at USD 31.5 billion in 2024 and is expected to grow from USD 33.2 billion in 2025 to USD 56.0 billion by 2035, registering a CAGR of 5.4% during the forecast period from 2026 to 2035. Increasing demand for blood transfusions, rising prevalence of chronic diseases, growing surgical volumes, and advances in blood-component processing and plasma-derived therapies are supporting market expansion.
North America is expected to remain the leading regional market, supported by advanced healthcare infrastructure, established blood-collection systems, and high demand for transfusion and plasma-derived products. Among product types, red blood cells represent a major segment because of their extensive use in trauma care, surgery, anemia management, and other transfusion procedures. Growing investment in blood-processing technologies and improved storage systems is further supporting market development.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/blood-product-market
Key Companies in the Blood Product Market
CSL Limited
Grifols S.A.
Takeda Pharmaceutical Company
Octapharma AG
Kedrion S.p.A.
Baxter International
Bio Products Laboratory
LFB S.A.
Sanquin
China Biologic Products Holdings
Haemonetics Corporation
Fresenius Kabi
Terumo Corporation
Macopharma
Cerus Corporation
The market is being driven by increasing demand for blood components and plasma-derived products across hospitals and specialized healthcare facilities. Rising surgical procedures, trauma cases, cancer treatments, and chronic diseases are contributing to transfusion requirements. Technological advances in blood screening, component separation, pathogen reduction, and plasma fractionation are improving product safety and quality. Growing awareness of blood donation and investments in healthcare infrastructure are also helping strengthen supply networks.
The Blood Product Market is segmented by product type, application, end user, and region. Product types include red blood cells, platelets, plasma, and cryoprecipitate, along with plasma-derived products. Applications cover blood transfusion, therapeutic treatment, and research, while end users include hospitals, blood banks, diagnostic laboratories, research institutions, and specialty healthcare facilities.
Recent Developments and Market Trends:
Advanced pathogen-reduction technologies are gaining adoption as healthcare systems seek to improve the safety of donated blood and blood components.
Automation in blood collection, processing, testing, and storage is increasing efficiency and helping blood banks manage growing operational requirements.
Plasma-derived therapies are receiving increased attention because of their applications in immunodeficiency, bleeding disorders, and other chronic conditions.
Improved cold-chain and blood-storage technologies are supporting better preservation and management of blood components.
Digital tracking and inventory-management systems are increasingly being adopted to improve blood-product traceability and reduce wastage.
Growing awareness campaigns and organized donation programs are supporting efforts to strengthen blood-collection networks and maintain adequate supplies.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Blood Product Market through 2035.
Analyze key segments based on product type, application, end user, and region.
Evaluate regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify major companies and understand their competitive positioning in the global blood-product industry.
Assess the impact of increasing transfusion requirements, chronic diseases, surgical procedures, and technological advancements on market growth.
Understand emerging opportunities associated with plasma-derived therapies, pathogen reduction, automation, and digital blood-management systems.
Future Outlook:
The global Blood Product Market is expected to maintain strong growth through 2035 as healthcare systems continue to require reliable supplies of blood components and plasma-derived therapies. Increasing surgical procedures, trauma care, chronic disease management, and advances in blood-processing technologies are expected to sustain demand. Investments in donation infrastructure, pathogen reduction, automation, storage technologies, and plasma fractionation are likely to create additional opportunities while improving the safety and efficiency of blood-product supply chains.
➤➤Explore Our Latest Related Reports:
